Understanding meningococcal disease: studying patient genomes and their disease causing bacteria

Understanding meningococcal disease by simultaneously studying genetic blueprints of patients and the meningococci causing their illness

Researchers
Dr Shamez Ladhani, Dr Mary Ramsay, Prof Ray Borrow, Prof Martin Maiden, Prof Christoph Tang.
Start Date
01 Jun 2017
Category
Prevention
Organisation
Public Health England, London, UK, Public Health England, Manchester, UK, University of Oxford, Oxford, UK.

What is this project about?

This project provides a unique opportunity for the genomes of patients to be linked together with the genomes of the meningococci that caused disease. This will be a unique database of human-bacteria genome pairs that will allow investigators to study interactions at an individual level and relate them to clinical disease and outcomes. 

The research team will examine genetic sequences for variations in critical genes, initially focusing on the human complement system and the respective meningococcal binding proteins which have been identified as major risk factors, as well as any novel interactions that could potentially have implications for next generation meningococcal vaccines.

Aims

  • To develop a unique anonymised database with individual level data linking whole genome sequences from patients with laboratory confirmed invasive meningococcal disease with clinical course of illness and whole genome sequences from the responsible meningococci (PHE)
  • To analyse the whole genome human and meningococcal data pairs to better understand critical interactions at a genetic level (PHE)
  • To visualise potential interactions through computer modelling (University of Oxford)

Why is it important?

Although large scale genetic studies involving several thousand patients with meningococcal disease have already been performed and important genetic markers have been identified that make some people more susceptible to this deadly infection, it is clear that we are only studying half the picture. In order to truly understand how humans interact with bacteria, we need to study the genetic blueprint of patients with meningococcal disease alongside the genetic blueprint of the particular bacterium that cause their illness. Together with the clinical information collected by PHE through national surveillance, these researchers will create a single database that will become an invaluable resource for decades to come.

Potential outcomes

In the short term, the team will develop a unique database for researchers around the world that will contain whole genome data for individual patient-meningococcus pairs, alongside important clinical data. 

Other studies have already identified individual variations in the human genome, mainly in genes encoding parts of the immune system, that are linked to disease outcome. Using the database, the team will investigate how these genetic variations lead to changes in the way they interact with their meningococcal counterparts. 

Continuing advances in information technology should also allow more complex analyses to be performed, such as looking for genetic variations along whole pathways rather than restricting to specific genes that code for individual proteins.

As the meningococcal B vaccine is introduced, the database will also include any cases of MenB disease in children who have already been vaccinated, allowing invaluable insight into how the vaccine works and why vaccine failure has occurred. 

In the longer term, the preliminary genomic analyses performed will allow for further work on interactions between bacteria and the people they infect, potentially enabling new vaccine targets to be identified.

Since the charity was founded in 1989, we have awarded 161 research grants. The total value of our investment in vital scientific research is over £19.1 million (€24.7 million).
We take action that benefits people directly, including training health professionals and providing support and information services.
We call for positive change as a united voice against meningitis and septicaemia, and a dedicated champion for those it affects.
We've invested nearly £20 million into meningitis research since 1989. Now, we're looking back at our most incredible achievements so far.
Give researchers the clues to help defeat meningitis
Give researchers the clues to help defeat meningitis
£160/€190/$214 decodes the genetic information in a sample of meningococcal bacteria. This information helps us to track new forms of meningitis and campaign to introduce new vaccines.
Share this
Liz Rodgers
Research Officer

Hi, I’m Liz and I’m MRF's Research Officer.

If you’d like to know more about this area of MRF's work, do get in touch.

Tel: 0333 405 6258